(MedPage Today) — FDA officials have outlined their new approach to COVID-19 vaccine approvals, allowing immunogenicity endpoints for high-risk groups, while calling for randomized controlled trials for those at lower risk.
FDA Commissioner Marty…
Source link : https://www.medpagetoday.com/infectiousdisease/covid19vaccine/115667
Author :
Publish date : 2025-05-20 15:10:00
Copyright for syndicated content belongs to the linked Source.
